Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
396 studies found for:    nasopharyngeal cancer | "Nasopharyngeal Carcinoma"
Show Display Options
Rank Status Study
1 Not yet recruiting Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli
Condition: Nasopharyngeal Carcinoma
Intervention:
2 Unknown  Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Conditions: Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma
Intervention: Drug: Famitinib
3 Recruiting Screening for Nasopharyngeal Carcinoma in High Risk Populations
Conditions: Nasopharyngeal Cancer;   Screening
Intervention:
4 Recruiting The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT
Condition: Nasopharyngeal Carcinoma
Interventions: Radiation: SIB-IMRT;   Drug: Cisplatin
5 Completed EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
Conditions: Nasopharyngeal Cancer;   EBV Infections
Interventions: Biological: EBV specific CTL Infusion;   Biological: Anti CD45 monoclonal antibody
6 Recruiting A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: neoadjuvant chemotherapy plus concurrent chemoradiotherapy
7 Recruiting Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
8 Terminated SOX as Salvage Treatment in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: S-1 plus oxaliplatin
9 Completed Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Biological: DNAzyme targeting EBV-LMP1 (DZ1);   Other: Saline
10 Unknown  Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-Up of Nasopharyngeal Carcinoma.
Condition: Nasopharyngeal Carcinoma
Intervention:
11 Completed Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)
Condition: Nasopharyngeal Carcinoma
Intervention:
12 Completed Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount
Condition: Nasopharyngeal Carcinoma
Intervention:
13 Terminated Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Cetuximab
14 Completed Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Radiation: Late-course accelerated hyperfractionated IMRT;   Drug: Concomitant cisplatin chemotherapy;   Radiation: Conventionally fractionated IMRT
15 Active, not recruiting Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: endostatin
16 Completed Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
Condition: Nasopharyngeal Carcinoma
Intervention:
17 Recruiting Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
Condition: Nasopharyngeal Carcinoma
Interventions: Dietary Supplement: nitrate supplementation;   Dietary Supplement: Placebo
18 Unknown  Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Cetuximab;   Drug: Cisplatin;   Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy
19 Completed The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: cisplatin
20 Completed Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma;   Adverse Effect of Radiation Therapy;   Brain Necrosis
Interventions: Drug: bevacizumab;   Drug: Methylprednisolone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years